MYSZ.NASDAQMy Size, INC

Form 4: My Size CGO Granted 110,000 Restricted Shares

Sentiment:

Insider Transaction Report


My Size, Inc.'s Chief Growth Officer, Borja Cembrero Saralegui, was granted 110,000 restricted shares of common stock with various vesting conditions.

Summary

  • Borja Cembrero Saralegui, Chief Growth Officer of My Size, Inc. (MYSZ), acquired 110,000 shares of common stock on December 15, 2025.
  • The shares were granted as restricted stock under the My Size, Inc. 2017 Equity Incentive Plan at a price of $0 per share.
  • Following this transaction, the Chief Growth Officer beneficially owns 117,965 shares.
  • The vesting schedule for the 110,000 restricted shares is as follows:
  • 10,000 shares vested immediately upon the grant date (December 15, 2025).
  • 40,000 shares will vest in three equal annual installments, with 1/3 vesting on January 1, 2026, January 1, 2027, and January 1, 2028, contingent on continued service.
  • Up to 60,000 shares are performance-based, vesting upon the achievement of specific profit and business targets, also subject to continued service.

Sentiment

Score: 6

Explanation: The filing reports a standard equity compensation grant to a key executive, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests. There are no immediate negative financial implications beyond potential minor dilution, which is expected with such plans.

Positives

  • The grant of restricted shares aligns the Chief Growth Officer's interests with those of shareholders, incentivizing long-term performance.
  • Performance-based vesting for up to 60,000 shares directly ties a significant portion of compensation to the achievement of company profit and business targets.

Negatives

  • The issuance of 110,000 new shares could lead to minor dilution for existing shareholders, although this is a standard aspect of equity compensation plans.

Risks

  • The vesting of up to 60,000 restricted shares is contingent on achieving specific profit and business targets, meaning the full grant may not materialize if these targets are not met.
  • Continued service is a condition for vesting for 100,000 of the 110,000 shares, introducing a risk of forfeiture if the reporting person leaves the company.

Future Outlook

The grant structure, particularly the performance-based vesting for up to 60,000 shares, indicates a focus on achieving specific profit and business targets in the future. The multi-year vesting schedule for 40,000 shares also suggests an expectation of continued service and long-term commitment from the Chief Growth Officer through at least January 2028.

Industry Context

The grant of restricted stock to a Chief Growth Officer is a common practice in the technology and growth-oriented sectors to attract, retain, and incentivize key executives. Equity compensation plans are widely used to align executive performance with shareholder value creation, particularly in companies like My Size, Inc. [MYSZ] that may be focused on scaling operations and achieving specific growth milestones.

Comparison to Industry Standards

  • The structure of this equity grant, combining immediate vesting, time-based vesting, and performance-based vesting, is consistent with common industry practices for executive compensation.
  • Many companies, including peers in the retail technology or e-commerce solutions space, utilize similar multi-faceted vesting schedules to balance retention incentives with performance alignment.
  • For example, companies like Shopify or Farfetch often use a mix of time-based and performance-based Restricted Stock Units (RSUs) for their senior leadership to drive strategic objectives and long-term value.
  • The $0 grant price is standard for restricted stock awards.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Equity Incentive Plan UtilizationGrant of restricted shares to the Chief Growth Officer under the existing My Size, Inc. 2017 Equity Incentive Plan.12/15/2025Reinforces the company's executive compensation strategy and aligns executive incentives with long-term shareholder value.

Related Party Transactions

  • The transaction involves the grant of equity compensation to an executive officer, which is a common form of related party transaction in the context of executive compensation.

Stakeholder Impact

  • Shareholders: Potential for minor dilution from the issuance of new shares, but also benefit from increased alignment of executive incentives with company performance and long-term value creation.
  • Employees: The grant to a key executive may signal confidence in the company's future and its ability to attract and retain talent.
  • Chief Growth Officer (Borja Cembrero Saralegui): Receives significant equity compensation, providing a strong incentive for continued service and achievement of company targets.

Next Steps

  • Achievement of profit and business targets for the vesting of up to 60,000 performance-based restricted shares.
  • Annual vesting events for 40,000 restricted shares on January 1, 2026, January 1, 2027, and January 1, 2028.

Key Dates

DateDescription
12/15/2025Date of transaction and grant of 110,000 restricted shares, with 10,000 shares vesting immediately.
12/17/2025Date the Form 4 was signed by Borja Cembrero Saralegui.
01/01/2026First annual vesting date for 1/3 of 40,000 restricted shares.
01/01/2027Second annual vesting date for 1/3 of 40,000 restricted shares.
01/01/2028Third annual vesting date for 1/3 of 40,000 restricted shares.

Keywords

MYSZ, My Size, restricted stock, equity incentive, executive compensation, Form 4, insider transaction

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.